Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Amneal Pharmaceuticals Inc’s stock clocked out at $9.75, down -2.21% from its previous closing price of $9.97. In other words, the price has decreased by -$2.21 from its previous closing price. On the day, 1.35 million shares were traded. AMRX stock price reached its highest trading level at $10.09 during the session, while it also had its lowest trading level at $9.685.
Ratios:
To gain a deeper understanding of AMRX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 37.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.31. For the most recent quarter (mrq), Quick Ratio is recorded 0.88 and its Current Ratio is at 1.43.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on June 06, 2025, initiated with a Buy rating and assigned the stock a target price of $12.
On February 24, 2025, JP Morgan Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $9 to $12.
JP Morgan Upgraded its Underweight to Neutral on September 06, 2024, while the target price for the stock was maintained at $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 27 ’25 when Kiely John sold 32,000 shares for $9.23 per share. The transaction valued at 295,360 led to the insider holds 225,433 shares of the business.
Kiely John bought 32,000 shares of AMRX for $293,810 on Aug 27 ’25. On Aug 22 ’25, another insider, Shah Nikita, who serves as the Executive Vice President of the company, sold 114,492 shares for $9.66 each. As a result, the insider received 1,105,993 and left with 152,743 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMRX now has a Market Capitalization of 3062273024 and an Enterprise Value of 5634271232. As of this moment, Amneal’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1523.44, and their Forward P/E ratio for the next fiscal year is 10.90. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 65.30. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.07. Its current Enterprise Value per Revenue stands at 1.975 whereas that against EBITDA is 9.012.
Stock Price History:
The Beta on a monthly basis for AMRX is 1.21, which has changed by 0.10669696 over the last 52 weeks, in comparison to a change of 0.1443547 over the same period for the S&P500. Over the past 52 weeks, AMRX has reached a high of $10.68, while it has fallen to a 52-week low of $6.68. The 50-Day Moving Average of the stock is 1.74%, while the 200-Day Moving Average is calculated to be 16.45%.
Shares Statistics:
It appears that AMRX traded 1.60M shares on average per day over the past three months and 1697320 shares per day over the past ten days. A total of 314.04M shares are outstanding, with a floating share count of 144.96M. Insiders hold about 53.84% of the company’s shares, while institutions hold 42.07% stake in the company. Shares short for AMRX as of 1759190400 were 5694704 with a Short Ratio of 3.55, compared to 1756425600 on 5109400. Therefore, it implies a Short% of Shares Outstanding of 5694704 and a Short% of Float of 2.8199999.
Earnings Estimates
Its stock is currently analyzed by 4.0 different market analysts. The consensus estimate for the next quarter is $0.16, with high estimates of $0.19 and low estimates of $0.14.
Analysts are recommending an EPS of between $0.78 and $0.73 for the fiscal current year, implying an average EPS of $0.76. EPS for the following year is $0.89, with 4.0 analysts recommending between $0.91 and $0.88.
Revenue Estimates
In. The current quarter, 4 analysts expect revenue to total $769.39M. It ranges from a high estimate of $775.62M to a low estimate of $760.94M. As of. The current estimate, Amneal Pharmaceuticals Inc’s year-ago sales were $702.47MFor the next quarter, 4 analysts are estimating revenue of $808.33M. There is a high estimate of $826.9M for the next quarter, whereas the lowest estimate is $792.41M.
A total of 4 analysts have provided revenue estimates for AMRX’s current fiscal year. The highest revenue estimate was $3.01B, while the lowest revenue estimate was $2.97B, resulting in an average revenue estimate of $3B. In the same quarter a year ago, actual revenue was $2.79BBased on 4 analysts’ estimates, the company’s revenue will be $3.19B in the next fiscal year. The high estimate is $3.22B and the low estimate is $3.14B.
